Cargando…

Association between Polymorphisms in the TSHR Gene and Graves' Orbitopathy

BACKGROUND: Graves' orbitopathy (GO) as well as Graves' disease (GD) hyperthyroidism originate from an autoimmune reaction against the common auto-antigen, thyroid-stimulating hormone receptor (TSHR). GO phenotype is associated with environmental risk factors, mainly nicotinism, as well as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jurecka-Lubieniecka, Beata, Ploski, Rafal, Kula, Dorota, Szymanski, Konrad, Bednarczuk, Tomasz, Ambroziak, Urszula, Hasse-Lazar, Kornelia, Hyla-Klekot, Lidia, Tukiendorf, Andrzej, Kolosza, Zofia, Jarzab, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111286/ https://www.ncbi.nlm.nih.gov/pubmed/25061884 http://dx.doi.org/10.1371/journal.pone.0102653

Ejemplares similares

Differences in Gene-Gene Interactions in Graves’ Disease Patients Stratified by Age of Onset
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2016)

Association between Age at Diagnosis of Graves' Disease and Variants in Genes Involved in Immune Response
por: Jurecka-Lubieniecka, Beata, et al.
Publicado: (2013)

Thyroid Stimulating Hormone Receptor (TSHR) Intron 1 Variants Are Major Risk Factors for Graves' Disease in Three European Caucasian Cohorts
por: Płoski, Rafał, et al.
Publicado: (2010)

Presentation of points of general discussion and voting among the speakers of the European Thyroid Association-Cancer Research Network (ETA-CRN) meeting in Lisbon, 2009, entitled ”European comments to ATA medullary thyroid cancer guidelines”
por: Jarząb, Barbara, et al.
Publicado: (2013)

Comparison of clinical examination with orbital MRI evaluation in patients with thyroid orbitopathy - do we need imaging and when?
por: Król, Aleksandra, et al.
Publicado: (2013)

A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy
por: Cui, Xuejiao, et al.
Publicado: (2023)

The Genetic Basis of Graves' Disease
por: Płoski, Rafał, et al.
Publicado: (2011)

Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy
por: Bednarczuk, Tomasz, et al.
Publicado: (2019)

Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy
por: Miśkiewicz, Piotr, et al.
Publicado: (2018)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Clinical utility of TSH receptor antibody levels in Graves’ orbitopathy: a comparison of two TSH receptor antibody immunoassays
por: Bluszcz, Gabriela A., et al.
Publicado: (2018)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Heterogeneity of the Clinical Presentation of the MEN1 LRG_509 c.781C>T (p.Leu261Phe) Variant Within a Three-Generation Family
por: Gilis-Januszewska, Aleksandra, et al.
Publicado: (2021)

High-dose intravenous methylprednisolone therapy in patients with Graves’ orbitopathy is associated with the increased activity of factor VIII
por: Miśkiewicz, P., et al.
Publicado: (2018)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

Simultaneous induction of Graves’ hyperthyroidism and Graves’ ophthalmopathy by TSHR genetic immunization in BALB/c mice
por: Xia, Nan, et al.
Publicado: (2017)

Therapy of moderate-to-severe Graves’ orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density
por: Rymuza, Joanna, et al.
Publicado: (2018)

Correlation of TSHR and CTLA-4 Single Nucleotide Polymorphisms with Graves Disease
por: Sun, Weihua, et al.
Publicado: (2019)

Regulation of TSHR Expression in the Thyroid and Thymus May Contribute to TSHR Tolerance Failure in Graves' Disease Patients via Two Distinct Mechanisms
por: Marín-Sánchez, Ana, et al.
Publicado: (2019)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

An Intronic HCP5 Variant Is Associated With Age of Onset and Susceptibility to Graves Disease in UK and Polish Cohorts
por: Lane, Laura Claire, et al.
Publicado: (2020)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Association of TLR7 and TSHR copy number variation with Graves’ disease and Graves’ ophthalmopathy in Chinese population in Taiwan
por: Liao, Wen-Ling, et al.
Publicado: (2014)

Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves’ Orbitopathy
por: Miskiewicz, Piotr, et al.
Publicado: (2018)

A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype–Phenotype Correlations
por: Soczomski, Przemysław, et al.
Publicado: (2021)

Association between TSHR gene polymorphism and the risk of Graves' disease: a meta-analysis
por: Qian, Wei, et al.
Publicado: (2016)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_du6qnulo2t41658bmjou608k8f